In people with advanced liver cirrhosis, a decrease in the gut microbes' ability to produce certain metabolic compounds is linked to lower overall microbial numbers and an overgrowth of Enterococcus...

Pro

Against

Mechanism

Synthesis from 1 study

How it works

When the good gut bacteria disappear, they stop making the chemicals that keep the gut lining strong. This lets harmful bacteria take over and leak into the blood, which turns on the immune system and causes inflammation throughout the body.

Most probable mechanism

In Simple Terms

When the gut has too few good bacteria, it can't make enough of the chemicals that feed the gut lining and keep it tight. This lets harmful bacteria like Enterococcus take over, and the gut becomes leaky. Toxins from these bacteria then escape into the bloodstream, triggering widespread inflammation throughout the body.

Causal chain

Decreased abundance and diversity of commensal bacteria reduces the production of short-chain fatty acids and secondary bile acids

Verified by multiple studies

which leads to

Loss of short-chain fatty acids deprives colonocytes of their primary energy source, impairing tight junction integrity and increasing intestinal permeability

Verified by multiple studies

which leads to

Reduced microbial competition and absence of antifungal metabolites allow Enterococcus species to dominate the gut microbiota

Verified by multiple studies

which leads to

Increased intestinal permeability enables translocation of bacterial cell wall components and other pathogen-associated molecules into the portal circulation

Verified by multiple studies

which leads to

Translocated microbial molecules activate liver and systemic immune cells through pattern recognition receptors, triggering sustained release of pro-inflammatory cytokines and macrophage activation markers

Verified by multiple studies

which leads to

Chronic systemic inflammation promotes immune dysfunction and increases susceptibility to infections and organ decompensation

Verified by multiple studies

Evidence from Studies

Supporting (1)

Community contributions welcome

Distinct clusters of bacterial and fungal microbiota in end-stage liver cirrhosis correlate with antibiotic treatment, intestinal barrier impairment, and systemic inflammation

Cross-Sectional Study

Human

2025 Dec

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Distinct clusters of bacterial and fungal microbiota in end-stage liver cirrhosis correlate with antibiotic treatment, intestinal barrier impairment, and systemic inflammation

Score: 44

DOI: 10.1080/19490976.2025.2487209

Similar Assertions

In people with advanced liver cirrhosis, an imbalance in gut bacteria—specifically high levels of Enterococcus, low bacterial variety, and reduced production of certain bacterial metabolites—is linked to higher levels of a protein that weakens the gut barrier, more widespread inflammation, and more frequent fungal infections.

86%

In patients with advanced liver cirrhosis, the presence of Bifidobacteria as the dominant gut bacteria is associated with higher bacterial diversity, more total bacteria, fewer fungi, and lower levels of systemic inflammation compared to cases where Enterococcus is the dominant gut bacterium.

77%

In patients with advanced liver cirrhosis, antibiotic use is linked to changes in the gut microbiome, including fewer types of bacteria, a rise in Enterococcus bacteria, and increased Candida fungi.

74%